CN Bio, an “organ-on-a-chip” company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), has announced the commercial launch of its Oncology Service in response to the global need to improve cancer drug discovery approval rates.   Understanding the relationship between pharmacokinetics, pharmacodynamics (PK/PD) and efficacy is critical to the successful development of new medicines, but at present this relationship is primarily investigated using animal ...